ODE V Deputy Bull Will Step In "As Needed" For Novartis-Bound DeLap
Executive Summary
FDA Office of Drug Evaluation V Deputy Director Jonca Bull, MD, is serving as the office's acting director in areas where departing Director Robert DeLap, MD/PhD, has conflicts of interest.
You may also be interested in...
ODE II Director Is Pulmonary & Allergy Division Chief Meyer
Pulmonary & Allergy Drug Products Division Director Robert Meyer, MD, will become Office of Drug Evaluation II director effective June 16
ODE II Director Is Pulmonary & Allergy Division Chief Meyer
Pulmonary & Allergy Drug Products Division Director Robert Meyer, MD, will become Office of Drug Evaluation II director effective June 16
Femara First-Line Breast Cancer Label Includes Tamoxifen Superiority Claim
Novartis' Femara (letrozole) first-line breast cancer approval Jan. 10 is based on superiority over tamoxifen (AstraZeneca's Nolvadex and Barr's generic).